MORRISVILLE, N.C., Dec. 9, 2014 (GLOBE NEWSWIRE) -- nContact, a leader in the development of Arrhythmia Disease Management Programs, announced that CEO John Funkhouser was invited to speak at the Piper Jaffray 26th Annual Healthcare Conference in New York, NY, last week. The talk was titled "Expanding the Boundaries of Electrophysiology Ablation," and was presented to an audience that included healthcare executives, industry thought leaders, and investors. The presentation focused on the need to redefine the role of Electrophysiology by delivering strong clinical and economic value in the ever-changing climate of managed care.
"Arrhythmias are the fastest growing segment of cardiology and it is critical to provide viable new approaches through a long-term Arrhythmia Disease Management Program," stated Funkhouser. "The future of cardiac patient care will be measured by the ability to access underserved populations and provide a multidisciplinary approach that collaborates across the entire cardiovascular services line."
The multidisciplinary Convergent Procedure is performed in a single setting in the electrophysiology lab. The epicardial lesions are created first under direct endoscopic visualization by a surgeon, through a 2 cm incision in the abdomen, with no chest incisions or ports. The endocardial lesions are created by an electrophysiologist, using specialized mapping and diagnostics to ensure a comprehensive approach.
Funkhouser continued, "With ablation standardization comes consistency and predictability, both of which are required under value-based care. In addition, by leveraging existing technologies and techniques, hospitals can realize healthcare system savings, driving their profitability and expanding their referral network. All of these components together bring a win-win for all stakeholders."
About nContact, Inc.
nContact's mission is to transform the underserved arrhythmia market through the advancement of less invasive ablation alternatives for cardiac arrhythmias. The Company is conducting the CONVERGE IDE Clinical Trial, the first head-to-head study to evaluate the Convergent Procedure to catheter ablation in persistent atrial fibrillation patients. The Company's lead technology, EPi-Sense® Coagulation System with VisiTrax®, has CE Mark approval in Europe for the coagulation of cardiac tissue in the treatment of atrial fibrillation and atrial flutter. The EPi-Sense Coagulation System with VisiTrax is indicated for endoscopic coagulation of cardiac tissue in the U.S. nContact was founded in 2005 and is headquartered in Morrisville, North Carolina, USA. For more information, visit www.ncontactinc.com.